Terms: = Lung cancer AND PWWP2A, Q8IYR3_HUMAN, Q96N64, MST101, MGC132770, KIAA1935, ENSG00000170234, 114825 AND Treatment
14414 results:
1. Prostaglandin E2 in the Tumor Microenvironment, a Convoluted Affair Mediated by EP Receptors 2 and 4.
Santiso A; Heinemann A; Kargl J
Pharmacol Rev; 2024 May; 76(3):388-413. PubMed ID: 38697857
[TBL] [Abstract] [Full Text] [Related]
2. The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability.
Abad E; Sandoz J; Romero G; Zadra I; Urgel-Solas J; Borredat P; Kourtis S; Ortet L; Martínez CM; Weghorn D; Sdelci S; Janic A
J Exp Clin Cancer Res; 2024 Apr; 43(1):127. PubMed ID: 38685100
[TBL] [Abstract] [Full Text] [Related]
3. [Interpretation of global lung cancer statistics].
Cai L; Zhu CX; Zhang XL; Fang Y; Yang HY; Guo LW
Zhonghua Liu Xing Bing Xue Za Zhi; 2024 Apr; 45(4):585-590. PubMed ID: 38678357
[TBL] [Abstract] [Full Text] [Related]
4. A vascularized breast cancer spheroid platform for the ranked evaluation of tumor microenvironment-targeted drugs by light sheet fluorescence microscopy.
Ascheid D; Baumann M; Pinnecker J; Friedrich M; Szi-Marton D; Medved C; Bundalo M; Ortmann V; Öztürk A; Nandigama R; Hemmen K; Ergün S; Zernecke A; Hirth M; Heinze KG; Henke E
Nat Commun; 2024 Apr; 15(1):3599. PubMed ID: 38678014
[TBL] [Abstract] [Full Text] [Related]
5. Curcumin Alone and Combined With PI3K Inhibitors Elicits Positive Effects on Oropharyngeal cancer Cell Lines Regardless of HPV Status.
Lukoceviciute M; Zupancic M; Kostopoulou ON; Holzhauser S; Dalianis T
Anticancer Res; 2024 May; 44(5):1863-1876. PubMed ID: 38677772
[TBL] [Abstract] [Full Text] [Related]
6. Effects of Reduced Extracellular Sodium Concentrations on Cisplatin treatment in Human Tumor Cells: The Role of Autophagy.
Naldi L; Fibbi B; Anceschi C; Nardini P; Guasti D; Peri A; Marroncini G
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673964
[TBL] [Abstract] [Full Text] [Related]
7. Potential application mechanism of traditional Chinese medicine in treating immune checkpoint inhibitor-induced colitis.
Wang J; Guo Z; Shen M; Xie Q; Xiang H
Front Immunol; 2024; 15():1366489. PubMed ID: 38660314
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy of Sorafenib-Based Therapies for Non-Small Cell lung cancer.
Hendrixson M; Gladkiy Y; Thyagarajan A; Sahu RP
Med Sci (Basel); 2024 Apr; 12(2):. PubMed ID: 38651414
[TBL] [Abstract] [Full Text] [Related]
9. Analysis of cancer-associated fibroblasts related genes identifies COL11A1 associated with lung adenocarcinoma prognosis.
Zheng H; Tan J; Qin F; Zheng Y; Yang X; Qin X; Liao H
BMC Med Genomics; 2024 Apr; 17(1):97. PubMed ID: 38649961
[TBL] [Abstract] [Full Text] [Related]
10. Discovery of gefitinib-1,2,3-triazole derivatives against lung cancer via inducing apoptosis and inhibiting the colony formation.
Gao E; Wang Y; Fan GL; Xu G; Wu ZY; Liu ZJ; Liu JC; Mao LF; Hou X; Li S
Sci Rep; 2024 Apr; 14(1):9223. PubMed ID: 38649732
[TBL] [Abstract] [Full Text] [Related]
11. Tumor growth-arrest effect of tetrahydroquinazoline-derivative human topoisomerase II-alpha inhibitor in HPV-negative head and neck squamous cell carcinoma.
Sarogni P; Brindani N; Zamborlin A; Gonnelli A; Menicagli M; Mapanao AK; Munafò F; De Vivo M; Voliani V
Sci Rep; 2024 Apr; 14(1):9150. PubMed ID: 38644364
[TBL] [Abstract] [Full Text] [Related]
12. [Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)].
Trastuzumab Deruxtecan Clinical Management Pathway and Adverse Reaction Management Consensus Expert Group
Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):304-318. PubMed ID: 38644266
[TBL] [Abstract] [Full Text] [Related]
13. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
14. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract] [Full Text] [Related]
15. TIMM17A overexpression in lung adenocarcinoma and its association with prognosis.
Miao L; Wu D; Zhao H; Xie A
Sci Rep; 2024 Apr; 14(1):8840. PubMed ID: 38632467
[TBL] [Abstract] [Full Text] [Related]
16. DNMT1/miR-152-3p/SOS1 signaling axis promotes self-renewal and tumor growth of cancer stem-like cells derived from non-small cell lung cancer.
Yuan Q; Wang R; Li X; Sun F; Lin J; Fu Z; Zhang J
Clin Epigenetics; 2024 Apr; 16(1):55. PubMed ID: 38622665
[TBL] [Abstract] [Full Text] [Related]
17. Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in cancer Therapy.
Kirschner T; Müller MP; Rauh D
J Med Chem; 2024 Apr; 67(8):6044-6051. PubMed ID: 38621359
[TBL] [Abstract] [Full Text] [Related]
18. EIF4A3 modulated circ_000999 promotes epithelial-mesenchymal transition in cadmium-induced malignant transformation through the miR-205-5p/ZEB1 axis.
Wang D; Chen S; Shao Y; Deng Y; Huang L
Environ Int; 2024 Apr; 186():108656. PubMed ID: 38621321
[TBL] [Abstract] [Full Text] [Related]
19. TIE1 promotes cervical cancer progression via Basigin-matrix metalloproteinase axis.
Liu P; Xie L; Wu Q; Huang L; Liu X; Li W; Cai J; Wang Z; Yang P; Cai L
Int J Biol Sci; 2024; 20(6):2297-2309. PubMed ID: 38617545
[No Abstract] [Full Text] [Related]
20. Proteasome activation is critical for cell death induced by inhibitors of polo-like kinase 1 (PLK1) in multiple cancers.
Wang Y; Wang G; Xiang W; Liu X; Jiang M; Hu J
Eur J Pharmacol; 2024 Jun; 972():176558. PubMed ID: 38614382
[TBL] [Abstract] [Full Text] [Related]
[Next]
